08:31 AM EDT, 09/30/2024 (MT Newswires) -- Organon (OGN) and Shanghai Henlius Biotech said Monday the phase 3 trial of investigational Perjeta biosimilar HLX11 met its primary endpoint of total pathological complete response.

The study compared the efficacy of HLX11 with Perjeta, or pertuzumab, in locally advanced breast cancer, the companies said. Secondary endpoints are currently being analyzed.

Henlius agreed to license the global commercialization rights, except in China, for HLX11 and another biosimilar candidate to Organon in 2022, the companies said.